TP022/#997 Sentinel-node biopsy in early stage ovarian cancer: preliminary results of a prospective multicentre study (SELLY)

• DOI: 10.1136/ijgc-2023-igcs.482
• Publication Date: 2023-11-08T07:00:54Z
• Authors: Camilla Nero; Nicolò Bizzarri; Stefano Di Berardino; Francesca Sillano; Giuseppe Vizzielli; Francesco Cosentino; Virginia Vargiu; Pierandrea De Iaco; Myriam Perrone; Enrico Vizza; Benito Chiofalo; Stefano Uccella; Fabio Ghezzi; Luigi Carlo Turco; Giacomo Corrado; Diana Giannarelli; Tina Pasciuto; Anna Fagotti; Giovanni Scambia
• Keywords: Lymphadenectomy

<h3>Introduction</h3> Sentinel-lymph node biopsy has safely replaced lymphadenectomy in the staging of many solid cancers. The aim this study was to evaluate sensitivity and specificity sentinel-lymph-node mapping compared with gold standard complete detecting metastatic disease for early stage ovarian cancer. <h3>Methods</h3> In SELLY multicentre, prospective, phase II trial (EUDRACT 2019–001088-58) patients presumed I-II epithelial cancer planned immediate or delayed minimally-invasive comprehensive were eligible inclusion. Patients received an injection indocyanine green followed by pelvic para-aortic lymphadenectomy. Seven centers from Italy participated trial. Negative sentinel lymph nodes (by haematoxylin eosin staining on sections) ultra-staged immunohistochemistry cytokeratin. primary endpoint, sentinel-lymph-node-based detection disease, defined as proportion node-positive successful who had correctly identified node. <h3>Current Trial Status</h3> Between March 2018 July 2022, 176 enrolled but only 174 interventions. 100 (58%) at least one 15 them (15.0%) positive nodes. Of latter, 11 (73.3%) a correct identification SLN. detail, 7 out required ultrastaging protocol. 4 negative Enrollment closed January 2023. Data analysis is about be completed.